Cargando…
Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients
Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a health concern for both unvaccinated and vaccinated individuals against coronavirus disease 2019 (COVID-19). To date, the humoral immune response following vaccination and natural infection remains uncharacterized...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372234/ https://www.ncbi.nlm.nih.gov/pubmed/37519697 http://dx.doi.org/10.1016/j.heliyon.2023.e18093 |
_version_ | 1785078327650811904 |
---|---|
author | Liu, Yu Zhao, Liunuobei Wang, Li Li, Yuxia Wang, Longde Yu, Bo Hu, Di Weng, Heng Guo, Jianwen Yang, Jinghua Yang, Jing Yu, Xiaobo |
author_facet | Liu, Yu Zhao, Liunuobei Wang, Li Li, Yuxia Wang, Longde Yu, Bo Hu, Di Weng, Heng Guo, Jianwen Yang, Jinghua Yang, Jing Yu, Xiaobo |
author_sort | Liu, Yu |
collection | PubMed |
description | Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a health concern for both unvaccinated and vaccinated individuals against coronavirus disease 2019 (COVID-19). To date, the humoral immune response following vaccination and natural infection remains uncharacterized in children ages 17 years and younger. To address this concern, we performed clinical and immunological analyses of IgM and IgG antibody responses to SARS-CoV-2 Omicron BA.2.38 infection in 64 pediatric patients. COVID-19 symptom severity decreased with age in pediatric patients, from 70.8% (17/24) in patients 0–2 years of age to 50% (6/12) and 50% (14/28) in patients 3–5 years and 6–17 years of age, respectively. Furthermore, fewer patients experienced symptoms when vaccinated with the CoronaVac or BBIBP-CorV vaccine (50%, 13/26) than unvaccinated patients (71%, 22/31). Using a protein array, we found that the Omicron BA.2.38 infection induced antibody responses to other Omicron variants (Omicron BA.1-BA.5), which increased with vaccination. Notably, non-Omicron and Omicron variants showed distinct serotypes. Altogether, our results provide insight into the clinical and immunological characteristics of pediatric patients with COVID-19 Omicron BA.2.38 who have and have not been vaccinated against COVID-19. These data may help develop more effective diagnostic tests and vaccines in the future. |
format | Online Article Text |
id | pubmed-10372234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103722342023-07-28 Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients Liu, Yu Zhao, Liunuobei Wang, Li Li, Yuxia Wang, Longde Yu, Bo Hu, Di Weng, Heng Guo, Jianwen Yang, Jinghua Yang, Jing Yu, Xiaobo Heliyon Research Article Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a health concern for both unvaccinated and vaccinated individuals against coronavirus disease 2019 (COVID-19). To date, the humoral immune response following vaccination and natural infection remains uncharacterized in children ages 17 years and younger. To address this concern, we performed clinical and immunological analyses of IgM and IgG antibody responses to SARS-CoV-2 Omicron BA.2.38 infection in 64 pediatric patients. COVID-19 symptom severity decreased with age in pediatric patients, from 70.8% (17/24) in patients 0–2 years of age to 50% (6/12) and 50% (14/28) in patients 3–5 years and 6–17 years of age, respectively. Furthermore, fewer patients experienced symptoms when vaccinated with the CoronaVac or BBIBP-CorV vaccine (50%, 13/26) than unvaccinated patients (71%, 22/31). Using a protein array, we found that the Omicron BA.2.38 infection induced antibody responses to other Omicron variants (Omicron BA.1-BA.5), which increased with vaccination. Notably, non-Omicron and Omicron variants showed distinct serotypes. Altogether, our results provide insight into the clinical and immunological characteristics of pediatric patients with COVID-19 Omicron BA.2.38 who have and have not been vaccinated against COVID-19. These data may help develop more effective diagnostic tests and vaccines in the future. Elsevier 2023-07-11 /pmc/articles/PMC10372234/ /pubmed/37519697 http://dx.doi.org/10.1016/j.heliyon.2023.e18093 Text en © 2023 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Liu, Yu Zhao, Liunuobei Wang, Li Li, Yuxia Wang, Longde Yu, Bo Hu, Di Weng, Heng Guo, Jianwen Yang, Jinghua Yang, Jing Yu, Xiaobo Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title | Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title_full | Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title_fullStr | Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title_full_unstemmed | Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title_short | Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients |
title_sort | clinical and humoral immune response characterization of sars-cov-2 omicron ba.2.38 infection in pediatric patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372234/ https://www.ncbi.nlm.nih.gov/pubmed/37519697 http://dx.doi.org/10.1016/j.heliyon.2023.e18093 |
work_keys_str_mv | AT liuyu clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT zhaoliunuobei clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT wangli clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT liyuxia clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT wanglongde clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT yubo clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT hudi clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT wengheng clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT guojianwen clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT yangjinghua clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT yangjing clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients AT yuxiaobo clinicalandhumoralimmuneresponsecharacterizationofsarscov2omicronba238infectioninpediatricpatients |